Florida Cerebrovascular Disease Biorepository and Genomics Center

Sponsor

Mayo Clinic (Other)

Overall Status

Recruiting

CT.gov ID

NCT05491980

Collaborator

(none)

5,000

Enrollment

Location

Anticipated Duration (Months)

208.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to create a state-wide biorepository and resource center for cerebrovascular diseases in Florida, which will include collecting medical history information and blood from families affected by cerebrovascular disease. The information and blood samples collected may be used in future research for the study of cerebrovascular disease and to learn about, prevent or treat other health problems.

Condition or Disease	Intervention/Treatment	Phase
Cerebrovascular Disease Ischemic Stroke Transient Ischemic Attack Intracerebral Hemorrhage Aneurysmal Subarachnoid Hemorrhage Vascular Dementia Anoxic Brain Injury Unruptured Intracranial Aneurysm Carotid Artery Stenosis Symptomatic Asymptomatic Carotid Artery Stenosis Non-Aneurysmal Perimesencephalic Subarachnoid Haemorrhage Cerebral Venous Thrombosis Moyamoya Disease Fibromuscular Dysplasia Subarachnoid Hemorrhage Leukoaraiosis Arteriovenous Fistula Reversible Cerebral Vasoconstriction Syndrome CADASIL

Study Design

Study Type:

Observational

Anticipated Enrollment :

5000 participants

Observational Model:

Other

Time Perspective:

Prospective

Official Title:

Creating a Florida Cerebrovascular Disease Biorepository and Genomics Center

Anticipated Study Start Date :

Aug 1, 2022

Anticipated Primary Completion Date :

Aug 1, 2024

Anticipated Study Completion Date :

Aug 1, 2024

Outcome Measures

Primary Outcome Measures

Stroke or TIA [12mo]
Number of participants to experience new diagnosis of TIA or stroke.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

• Affected and unaffected family members of diverse cerebrovascular conditions, including, but not limited to, ischemic stroke, transient ischemic attack (TIA), intracerebral hemorrhage (ICH), aneurysmal subarachnoid hemorrhage (aSAH), vascular dementia (VAD), anoxic brain injury, unruptured intracranial aneurysm (UIA), cavernous malformation, arteriovenous malformations (AVM), carotid and vertebral arterial dissections, symptomatic and asymptomatic cervical carotid artery atherosclerotic stenosis, non-aneurysmal perimesencephalic subarachnoid hemorrhage (naSAH), cerebral venous thrombosis (CVT), moyamoya disease, fibrosmuscular dysplasia (FMD), non-traumatic, angiography-negative subarachnoid hemorrhage, leukoaraiosis, arteriovenous fistula, reversible cerebral vasoconstriction syndrome (RCVS), and CADASIL.